The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: An open-label, non-randomised, multi-centre observational study - The Iran subgroup of the IMPROVE™ study

Endokrynologia Polska

Volumn 61, Issue 4, 2010, Pages 364-370

  Esteghamati, Alireza ^a   Rajabian, Reza ^b   Amini, Masoud ^c   Bahrami, Amir ^d   Khamseh, Mohammad Ebrahim ^e   Afkhami Ardekani, Mohammad ^f   Rizi, Ehsan Parvaresh ^g  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g NOVO NORDISK A S   (Denmark)

Author keywords

Insulin aspart; Quality of life; Type 2 diabetes

Indexed keywords

INSULIN; INSULIN ASPART; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IRAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OPEN STUDY; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT DURATION;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; IRAN; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 77957264821     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rohlfing CL, Wiedmeyer HM, Little RR et al. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 252: 275-278.
2. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885. (Pubitemid 36929359)
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
5. Wiseman MJ, Saunders AJ, Keen H et al. Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. N Engl J Med 1985; 312: 617-621.
6. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341: 1306-1309.
7. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-309. (Pubitemid 23210681)
8. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
9. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
10. Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther 2005. 27: 1113-1125.
11. Warren ML, Conway MJ, Klaff LJ et al. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract 2004; 66: 23-29.
12. Boehm BO, Home PD, Behrend C et al. Premixed insulin aspart 30 v. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-399.
13. Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006; 8: 58-66.
14. Standards of medical care in diabetes. Diabetes Care 2004; 27 (Suppl. 1): S15-S35.
15. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 494-495.
16. Kann PH, Wascher T, Zackova V et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006. 114: 527-532.
17. Esteghamati A, Meysamie A, Khalilzadeh O et al. Third national Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health 2009; 29: 167.
18. Esteghamati A, Khalilzadeh O, Anvari M et al. The economic costs of diabetes: a population-based study in Tehran, Iran. Diabetologia 2009; 52: 1520-1527.
19. Gumprecht J, Benroubi M, Borzi V et al. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract 2009; 63: 966-972.
20. Yang W, Ji Q, Zhu D et al. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care 2008. 31: 852-856.
21. Valensi P, Benroubi M, Borzi V et al. The IMPROVE study a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 2008; 62: 1809-1819.
22. Valensi P, Benroubi M, Borzi V et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract 2009; 63: 522-531.
23. Ligthelm RJ, Borzì V, Gumprecht J et al. Importance of observational studies in clinical practice. Clin Ther 2007; 29: 1284-1292. (Pubitemid 351181208)
24. Gough S. Post-marketing surveillance: a UK/European perspective. Curr Med Res Opin 2005; 21: 565-570.
25. Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res 2006; 15: 481-491.
26. Christiansen JS, Vaz JA, Metelko Z et al. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003. 5: 446-454.